Visit ten23.health

Overview

As drug development activities across biologics modalities continue to accelerate, small biotechs and large pharma companies will increasingly outsource key services which require unique and market tested expertise. 

Recognising this, we decided to create a development, manufacturing and testing company for biotech start-ups and the established pharmaceutical industry. 

Headquartered in Basel, Switzerland, ten23 health’s core service offering includes formulation development, drug product development and manufacturing, as well as testing services for sterile pharmaceutical products. These high-value services are critical to helping pharma and biotech customers turn a scientific concept and therapeutic modality into a viable sterile medicine that is optimised for manufacturability, patient access and ease of administration, and logistical favourability.

How we add value 

We partnered with a highly experienced team of experts, including Prof. Dr Hanns Christian Mahler, with a proven track record in pharmaceutical product design and development to launch ten23 health in 2021. 

Since then, we have supported the company’s acquisition of swissfillon, a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices, creating a vertically integrated CDMO with ten23’s Basel development lab and swissfillon’s scaled fill & finish manufacturing. 

As drug development activities across biologics modalities continue to accelerate, small biotechs and large pharma companies will increasingly outsource key services which require unique and market tested expertise. ten23 health will deliver services in an engrained, fair and sustainable manner, respecting the future of the planet and people’s health. 

Regulatory information
This transaction involved a recommendation of 3i Investments plc.